Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 30 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 45 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - pralsetinib - hard capsule - pralsetinib 100 mg - pralsetinib - - gavreto is indicated for the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc).- gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy.- gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - film coated tablets - pirfenidone 267 mg - pirfenidone - esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - film coated tablets - pirfenidone 801 mg - pirfenidone - esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf)..

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - risdiplam - powder for solution - risdiplam 60 mg/bottle - risdiplam - evrysdi is indicated for the treatment of spinal muscular atrophy (sma) types 1,2 and 3 in patients 2 months of age and older.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - satralizumab - solution for injection - satralizumab 120 mg / 1 ml - satralizumab - enspryng is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - film coated tablets - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - film coated tablets - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - baloxavir marboxil - film coated tablets - baloxavir marboxil 20 mg - baloxavir marboxil - xofluza is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. limitations of use: influenza viruses change over time and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use xofluza.